Evoke Pharma Q4 2023 GAAP EPS $(0.59) Misses $(0.50) Estimate, Sales $1.676M Beat $1.632M Estimate
Evoke Pharma Q4 2023 GAAP EPS $(0.59) Misses $(0.50) Estimate, Sales $1.676M Beat $1.632M Estimate
Evoke Pharma 2023年第四季度公認會計准則每股收益美元 (0.59) 未達到預期 (0.50) 美元，銷售額超過16.32億美元的預期
Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.50) by 18 percent. The company reported quarterly sales of $1.676 million which beat the analyst consensus estimate of $1.632 million by 2.70 percent. This is a 110.55 percent increase over sales of $796.000 thousand the same period last year.
Evoke Pharma（納斯達克股票代碼：EVOK）公佈的季度虧損爲每股0.59美元，比分析師普遍預期的0.50美元（0.50美元）低18％。該公司公佈的季度銷售額爲16.76萬美元，比分析師普遍預期的16.32億美元高出2.70％。這比去年同期的79.6萬美元的銷售額增長了110.55％。